Skip to main content

Table 3 Comparison of copy number variations (CNVs) between CAISMOV24 cell line and its primary low-grade serous ovarian carcinoma cells

From: CAISMOV24, a new human low-grade serous ovarian carcinoma cell line

Primary maligant cells CAISMOV24
Chromosome CNV Type Size (kbp) Cytoband interval Gene Count Chromosome CNV Type Size (kbp) Cytoband interval Gene Count
1 1 Gain 221 1p36.32(3,331,773–3,552,456)×3 6 1 3 Gain 113,168
144,332
317,481
1p36.33(2,173,472–2,286,640)×0–1
1p36.33(900,361–1,044,693)×2–3
1p36.32(3,324,208–3,641,689)×0–1
3
8
7
2 1 Gain 242, 771 2p25.3q37.3(12,770–242,783,384)×28–29 1494 2 1 cnLOH 242,76 2p25.3q37.3(15,702–242,775,910) hmz 1494
3 1 Gain 197,79 3p26.3q29(61,891–197,851,986)×3 1279 3 2 Loss
Gain
276
197,79
3q12.1(98,596,503–98,872,626)×0–1
3p26.3q29(61,891–197,851,986)×3
1
1278
5 1 Gain 180,606 5p15.33q35.3(113,576–180,719,789)×3 1035 5 1 Gain 180,606 5p15.33q35.3(113,576–180,719,789)×3 1035
6 1 Loss 127 6p25.3(254,282–381,137)×1 1 6 1 Loss 127 6p25.3(254,253–381,137)×1 1
7 3 Gain
Gain
Gain
7818
66,570
83,982
7q11.21q11.23(66,698,378–74,516,616)×3
7p22.3q11.21(43,360–66,613,020)×3
7q11.23q36.3(75,137,713–159,119,707)×3
58
418
659
7 4 Gain
Gain
Gain
Gain
1695
3221
72,589
80,786
7q11.23(72,692,112–74,386,749)×3
7q11.23q21.11(75,034,632–78,255,196)×3
7p22.3q11.23(43,360–72,632,831)×3
7q21.11q36.3(78,333,779–159,119,707)×3
33
39
436
626
8 4 Loss
Gain
Gain
Gain
140
4398
39,089
99,432
8p11.22(39,247,097–39,386,952)×2
8p11.22p11.1(39,388,765–43,786,723)×4
8p23.3p11.22(158,048–39,246,760)×4
8q11.1q24.3(46,863,521–146,295,771)×4
  8 4 Loss
Gain
Gain
Gain
140
4398
39,089
99,432
8p11.22(39,247,097–39,386,952)×1
8p11.22p11.1(39,388,765–43,786,723)×4
8p23.3p11.22(158,048–39,246,760)×4
8q11.1q24.3(46,863,521–146,295,771)×4
2
33
292
511
9 1 Loss 209 9p21.3(21,887,365–22,096,124)×1 4 9 3 Gain
Gain
Gain
679
3244
21,879
9q34.3(139,282,807–139,961,930)×3
9p21.3(22,086,839–25,330,810)×291–292
9p24.3p21.3(203,861–22,082,884)×2–3
45
5
102
       11 1 Gain 364 11p15.5(241,986–606,294)×3 21
12 4 Gain
Gain
Gain
Gain
9834
11,031
28,314
84,394
12q12q13.12(39,535,139–49,369,195)×29–30
12p13.33p13.2(173,786–11,204,306)×39–40
12p13.2q12(11,207,579–39,521,153)×39–40
12q13.12q24.33(49,385,726–133,777,902)×39–40
68
192
149
778
12 3 Loss
Gain
Gain
9499
11,276
23,369
12q12q13.11(39,441,095–48,940,506)×1
12p13.33p13.2(173,786–11,450,109)×39–40
12p13.2p11.1(11,466,434–34,835,837)×39–40
51
198
139
13 1 Gain 95,671 13q11q34(19,436,286–115,107,733)×3 459 13 1 Gain 95,671 13q11q34(19,436,286–115,107,733)×3 459
14 1 Gain 86,774 14q11.2q32.33(20,511,672–107,285,437)×2–3 770 14 2 Gain
Gain
13,876
71,619
14q32.12q32.33(93,408,967–107,285,437)×29–30
14q11.2q32.12(20,511,672–92,130,966)×29–30
238
521
16 1 cnLOH 90,074 16p13.3q24.3(89,560–90,163,275) hmz 955 16 5 Loss
Gain
Gain
Loss
cnLOH
124
143
236
291
82,965
16p13.3(7,094,531–7,218,941)×1
16p13.3(1,986,979–2,129,528)×3
16p13.3(1,052,879–1,288,518)×3
16p13.3(7,441,425–7,732,737)×1
16p13.3q24.3(7,198,476–90,163,275) hmz
1
18
6
1
734
19 1 Gain 1142 19p13.3(260,911–1,403,381)×24–25 51 19 1 Gain 1256 19p13.3(260,911–1,517,292)×24–25 58
20 3 Gain
Gain
Gain
1499
5355
55,959
20p13(61,568–1,560,550)×3
20q13.32q13.33(57,560,776–62,915,555)×3
20q13.32q13.33(57,560,776–62,915,555)×3
34
106
515
20 3 Gain
Gain
Gain
557
14,149
47,64
20p12.1(14,319,185–14,875,738)×3
20p13p12.1(61,568–14,210,343)×3
20p12.1q13.33(15,275,354–62,915,555)×3
2
134
518
22 1 Gain 512 22q11.22(22,943,460–23,455,803)×25–26 6 22 1 Gain 458 22q11.22(22,997,802–23,455,803)×24–25 4
X 3 Gain
Gain
Gain
182
201
384
Xq21.31(88,604,293–88,786,664)×3
Xp22.33(2,956,273–3,156,774)×3
Xq21.2(85,297,084–85,680,929)×3
0
1
2
X 1 Gain 74,778 Xp22.33q13.3(168,546–74,946,70n)×2–3 494
  1. CNV copy number variation; Column “Gene Count” refers to number of genes found in CNV sequence, cnLOH Copy neutral loss of heterozygosity; Cytoband interval based on assembly human genome hg19